Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Personalized Medicine Eliminates Need for Drug in Two Children

Published: Tuesday, February 05, 2013
Last Updated: Tuesday, February 05, 2013
Bookmark and Share
Risk of hypertension eliminated with $10,000 savings per patient through genomics.

Using genome-wide analysis, investigators at the Sainte-Justine University Hospital Research Center and the University of Montreal have potentially eliminated a lifetime drug prescription that two children with a previously unknown type of adrenal insufficiency had been receiving for 14 years. Over a lifespan, the adjustment in treatment represents an approximate saving of $10,000 in drug and test costs per patient. Moreover, the less invasive treatment regime can potentially reduce the lifetime risk of hypertension in the patients. “This is a real case of personalized medicine made possible today through the use of novel techniques in genomics,” stated Dr. Mark Samuels, lead author of a paper published on the subject in January 2013 in the Journal of Clinical Endocrinology and Metabolism. Dr. Johnny Deladoëy was the senior author of the article.

Fourteen years ago both children were diagnosed with adrenal insufficiency, a condition that occurs when the adrenal glands do not secrete enough hormones to control sugar and mineral levels in the blood. After having sequenced the part of the genome that codes for genes in one patient, the investigators identified mutations in POMC, the gene behind the disorder. They then showed that the disorder in the second patient was also caused by a similar mutation in the gene POMC. Identifying the causal gene allowed them to conclude that the only thing missing in the patients was the production of cortisol, the hormone that regulates blood sugar. They thus advised the patients to continue cortisol treatment, but that fludrocortisone treatment was unlikely to be necessary. So far, fludrocortisone has been stopped in one patient without any adverse effects, while the condition of the second patient is still being evaluated.

In addition to reducing the risks of hypertension induced by fludrocortisone and allowing the patients and their family to feel more confident about the origin of the disease, the investigators’ discovery made it possible to reduce by as much as $10,000 the health costs for patients with this type of adrenal insufficiency. Over a 70-year lifespan, this is what the fludrocortisone treatment and the blood tests required in the patients treated with it adds up to.

The physicians did not modify the treatment earlier in the children’s lives due to lack of a clear molecular diagnosis hence an imperfect understanding of the disease. Not only could withholding one of the replacement hormones have potentially led to a fatal outcome, but also analyzing the whole genome that led to the diagnosis would have been unthinkable just a few years ago. “Due to the astronomical costs associated previously with analyzing the whole genome, certain genes had to be targeted that were potentially responsible for the disorder and only these genes were analyzed in spite of the risk of not finding the right gene,” explains Dr. Samuels, a researcher in human genetics. Today, lower genome analysis costs make an analysis of the whole genome affordable.

Description of the study
The two children in the study were hospitalized at the ages of 4 months or 4 years respectively, for hypoglycemia and associated convulsions. A diagnosis of adrenal insufficiency was made and the two children were saved by administering replacement hormones. Their ACTH (the pituitary hormone that controls the adrenal gland) blood concentrations were very high, which seemed to implicate the adrenal gland. The adrenal gland produces two vital hormones: cortisol to regulate glycemia and aldosterone to control minerals. When in doubt, in the event of adrenal insufficiency, both hormone types (cortisol and fludrocortisone, an aldosterone analogue) are prescribed. Nevertheless, fludrocortisone treatment can lead to side effects such as hypertension.

Hoping to better target patient treatment, the investigators went about tracking down the exact cause of adrenal insufficiency. They proceeded to analyze part of the genome that codes for genes in one patient’s DNA (whole-genome sequencing being still too expensive for the time being). To their great surprise, the analysis indicated the presence of two mutations in POMC, the gene that codes for ACTH, in the patient. Direct sequencing of the POMC gene in DNA from the second patient confirmed the occurrence of one of the mutations in that child as well. The researchers then collaborated with Dr. Michel Bouvier (University of Montreal) and Dr. Nicole Gallo-Payet (University of Sherbrooke) to validate the discovery by performing in vitro tests on cells using two synthetic ACTHs produced for the experiment: one normal and the other carrying the mutation observed in both children. These studies showed that, while high levels were detected in the blood, the mutant ACTH was inactive. Due to technical limitations, the standard diagnostic test that detects ACTH was unable to distinguish between the normal and the mutated form found in the patients.

“The genome analysis allowed us to incriminate the POMC gene. Since the gene was not suspect according to the blood tests, we would have missed the cause of the disease without this new technique,” concludes Dr. Deladoëy, a physician and researcher in endocrinology and diabetology.

This case of personalized medicine made possible through novel genomic techniques is just the tip of the iceberg. In the near future, investigators hope to succeed in refining the treatment of many patients using these techniques.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
Searching Big Data Faster
Theoretical analysis could expand applications of accelerated searching in biology, other fields.
Growing Hepatitis C in the Lab
Recent discovery allows study of naturally occurring forms of hepatitis C virus (HCV) in the lab.
Inciting an Immune Attack on Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
Reprogramming Cancer Cells
Researchers on Mayo Clinic’s Florida campus have discovered a way to potentially reprogram cancer cells back to normalcy.
Genetic Overlapping in Multiple Autoimmune Diseases May Suggest Common Therapies
CHOP genomics expert leads analysis of genetic architecture, with eye on repurposing existing drugs.
Surprising Mechanism Behind Antibiotic-Resistant Bacteria Uncovered
Now, scientists at TSRI have discovered that the important human pathogen Staphylococcus aureus, develops resistance to this drug by “switching on” a previously uncharacterized set of genes.
How DNA ‘Proofreader’ Proteins Pick and Edit Their Reading Material
Researchers from North Carolina State University and the University of North Carolina at Chapel Hill have discovered how two important proofreader proteins know where to look for errors during DNA replication and how they work together to signal the body’s repair mechanism.
Fat in the Family?
Study could lead to therapeutics that boost metabolism.
Tissue Bank Pays Dividends for Brain Cancer Research
Checking what’s in the bank – the Brisbane Breast Bank, that is – has paid dividends for UQ cancer researchers.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!